Article Versions Notes

Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, et al. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine. 2020; 9(2):385. https://doi.org/10.3390/jcm9020385

Scarozza, Patrizio, Irene Marafini, Federica Laudisi, Edoardo Troncone, Heike Schmitt, Marco Vincenzo Lenti, Stefania Costa, Irene Rocchetti, Elena De Cristofaro, Silvia Salvatori, and et al. 2020. "Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab" Journal of Clinical Medicine 9, no. 2: 385. https://doi.org/10.3390/jcm9020385

Scarozza, P., Marafini, I., Laudisi, F., Troncone, E., Schmitt, H., Lenti, M. V., Costa, S., Rocchetti, I., De Cristofaro, E., Salvatori, S., Frezzati, L., Di Sabatino, A., Atreya, R., Neurath, M. F., Calabrese, E., & Monteleone, G. (2020). Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine, 9(2), 385. https://doi.org/10.3390/jcm9020385